Open Orphan Plc
ORPH.LN
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands. Open Orphan is led by a management team with deep industry and financial experience.
Related content
Press Releases
|
Open Orphan expands human challenge trial capacity with new volunteer recruitment centres
Press Releases
|
Open Orphan and hVIVO’s human vaccine trial for Covid-19 begins
Press Releases
|
Open Orphan has a great start to 2021 with key 12-month contract renewal
Press Releases
|
Open Orphan wins vaccine contract extension and announces toxicology study completion
Press Releases
|
“We are scaling-up rapidly and at minimum expense” – Open Orphan’s Cathal Friel on the pharma services firm’s exciting plans for 2021 and beyond
Press Releases
|
Open Orphan and Codagenix receive MHRA approval for Covid vaccine challenge study
Press Releases
|
Open Orphan continues to convert deal pipeline with key Venn contracts
Press Releases
|
Open Orphan strengthens board with Elaine Sullivan hire
Press Releases
|
Open Orphan leads weighty Wellcome Trust bid to define human challenge drug standards
Press Releases
|
Open Orphan lands another £2.5m flu challenge study contract
Press Releases
|
Open Orphan extends pharmacometrics relationship with tier 1 German pharma company
Press Releases
|
Open Orphan reveals transformational Covid-19 vaccine contract with UK government
Press Releases
|
Open Orphan hits record highs after winning £4.3m vaccine contract
Press Releases
|
Key human challenge expert Adrian Wildfire rejoins hVIVO for Open Orphan boost (ORPH)
Investing Ideas
|
Open Orphan reveals placing progress following hVIVO merger (ORPH)
Investing Ideas
|